Serbia

Serbia

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.7 (0.60 - 0.81) 2019 Modelled IHME
0.7 (0.60 - 0.79) 2018 Modelled IHME
0.7 (0.60 - 0.80) 2017 Modelled IHME
0.71 (0.61 - 0.81) 2016 Modelled IHME
0.73 (0.62 - 0.84) 2015 Modelled IHME
0.75 (0.64 - 0.85) 2014 Modelled IHME
0.76 (0.65 - 0.86) 2013 Modelled IHME
0.78 (0.67 - 0.88) 2012 Modelled IHME
0.8 (0.67 - 0.91) 2011 Modelled IHME
0.81 (0.68 - 0.93) 2010 Modelled IHME
0.83 (0.70 - 0.94) 2009 Modelled IHME
0.84 (0.71 - 0.97) 2008 Modelled IHME
0.85 (0.72 - 0.98) 2007 Modelled IHME
0.87 (0.74 - 1) 2006 Modelled IHME
0.88 (0.74 - 1.02) 2005 Modelled IHME
0.89 (0.76 - 1.02) 2004 Modelled IHME
0.9 (0.77 - 1.03) 2003 Modelled IHME
0.91 (0.78 - 1.04) 2002 Modelled IHME
0.92 (0.78 - 1.05) 2001 Modelled IHME
0.93 (0.79 - 1.06) 2000 Modelled IHME
0.94 (0.80 - 1.07) 1999 Modelled IHME
0.95 (0.81 - 1.08) 1998 Modelled IHME
0.96 (0.81 - 1.10) 1997 Modelled IHME
0.97 (0.82 - 1.11) 1996 Modelled IHME
0.97 (0.81 - 1.12) 1995 Modelled IHME
0.97 (0.81 - 1.12) 1994 Modelled IHME
0.97 (0.81 - 1.11) 1993 Modelled IHME
0.96 (0.81 - 1.10) 1992 Modelled IHME
0.95 (0.80 - 1.10) 1991 Modelled IHME
0.94 (0.78 - 1.08) 1990 Modelled IHME
0.98 (0.70 - 1.33) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.06 (0.04 - 0.08) 2019 Modelled IHME
0.07 (0.05 - 0.09) 2018 Modelled IHME
0.07 (0.05 - 0.09) 2017 Modelled IHME
0.06 (0.05 - 0.08) 2016 Modelled IHME
0.06 (0.04 - 0.08) 2015 Modelled IHME
0.06 (0.04 - 0.08) 2014 Modelled IHME
0.06 (0.04 - 0.07) 2013 Modelled IHME
0.06 (0.04 - 0.07) 2012 Modelled IHME
0.06 (0.04 - 0.07) 2011 Modelled IHME
0.06 (0.04 - 0.07) 2010 Modelled IHME
0.06 (0.05 - 0.08) 2009 Modelled IHME
0.08 (0.06 - 0.11) 2008 Modelled IHME
0.11 (0.08 - 0.15) 2007 Modelled IHME
0.15 (0.11 - 0.20) 2006 Modelled IHME
0.19 (0.14 - 0.25) 2005 Modelled IHME
0.25 (0.18 - 0.33) 2004 Modelled IHME
0.34 (0.25 - 0.44) 2003 Modelled IHME
0.44 (0.32 - 0.57) 2002 Modelled IHME
0.52 (0.38 - 0.67) 2001 Modelled IHME
0.57 (0.41 - 0.74) 2000 Modelled IHME
0.58 (0.42 - 0.76) 1999 Modelled IHME
0.6 (0.43 - 0.78) 1998 Modelled IHME
0.61 (0.44 - 0.80) 1997 Modelled IHME
0.61 (0.44 - 0.82) 1996 Modelled IHME
0.61 (0.44 - 0.83) 1995 Modelled IHME
0.61 (0.44 - 0.82) 1994 Modelled IHME
0.61 (0.43 - 0.80) 1993 Modelled IHME
0.6 (0.42 - 0.80) 1992 Modelled IHME
0.59 (0.41 - 0.79) 1991 Modelled IHME
0.57 (0.39 - 0.76) 1990 Modelled IHME
0.11 (0.06 - 0.17) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
18 (12 - 25) 2019 Modelled IHME
18 (12 - 25) 2018 Modelled IHME
18 (12 - 25) 2017 Modelled IHME
18 (12 - 25) 2016 Modelled IHME
18 (13 - 26) 2015 Modelled IHME
19 (13 - 26) 2014 Modelled IHME
19 (14 - 27) 2013 Modelled IHME
20 (14 - 28) 2012 Modelled IHME
20 (14 - 28) 2011 Modelled IHME
21 (15 - 29) 2010 Modelled IHME
21 (15 - 29) 2009 Modelled IHME
21 (15 - 29) 2008 Modelled IHME
21 (15 - 29) 2007 Modelled IHME
21 (15 - 29) 2006 Modelled IHME
21 (15 - 29) 2005 Modelled IHME
21 (15 - 29) 2004 Modelled IHME
22 (15 - 30) 2003 Modelled IHME
22 (15 - 30) 2002 Modelled IHME
22 (15 - 30) 2001 Modelled IHME
22 (15 - 31) 2000 Modelled IHME
22 (15 - 31) 1999 Modelled IHME
22 (15 - 31) 1998 Modelled IHME
22 (16 - 31) 1997 Modelled IHME
23 (16 - 31) 1996 Modelled IHME
23 (16 - 31) 1995 Modelled IHME
23 (16 - 32) 1994 Modelled IHME
23 (16 - 32) 1993 Modelled IHME
23 (16 - 32) 1992 Modelled IHME
23 (16 - 32) 1991 Modelled IHME
23 (16 - 32) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
99 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
99 2014 Survey/reported WHO/UNICEF
99 2013 Survey/reported WHO/UNICEF
99 2012 Survey/reported WHO/UNICEF
99 2011 Survey/reported WHO/UNICEF
99 2010 Survey/reported WHO/UNICEF
99 2009 Survey/reported WHO/UNICEF
99 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
98 2005 Survey/reported WHO/UNICEF
98 2004 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
91 2018 Survey/reported WHO/UNICEF
93 2017 Survey/reported WHO/UNICEF
91 2016 Survey/reported WHO/UNICEF
94 2015 Survey/reported WHO/UNICEF
92 2014 Survey/reported WHO/UNICEF
91 2013 Survey/reported WHO/UNICEF
97 2012 Survey/reported WHO/UNICEF
94 2011 Survey/reported WHO/UNICEF
89 2010 Survey/reported WHO/UNICEF
93 2009 Survey/reported WHO/UNICEF
93 2008 Survey/reported WHO/UNICEF
99 2007 Survey/reported WHO/UNICEF
93 2006 Survey/reported WHO/UNICEF
65 2005 Survey/reported WHO/UNICEF
89 2004 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
4 (2.60 - 6) 2010 Survey/reported EMCDDA, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2006
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.11 (0.90 - 1.37) 2019 Modelled IHME
1.1 (0.90 - 1.36) 2018 Modelled IHME
1.1 (0.89 - 1.35) 2017 Modelled IHME
1.09 (0.89 - 1.33) 2016 Modelled IHME
1.09 (0.89 - 1.32) 2015 Modelled IHME
1.09 (0.89 - 1.32) 2014 Modelled IHME
1.1 (0.90 - 1.34) 2013 Modelled IHME
1.11 (0.90 - 1.36) 2012 Modelled IHME
1.12 (0.90 - 1.38) 2011 Modelled IHME
1.13 (0.90 - 1.40) 2010 Modelled IHME
1.12 (0.90 - 1.38) 2009 Modelled IHME
1.12 (0.90 - 1.37) 2008 Modelled IHME
1.11 (0.89 - 1.36) 2007 Modelled IHME
1.1 (0.89 - 1.34) 2006 Modelled IHME
1.1 (0.88 - 1.34) 2005 Modelled IHME
1.1 (0.88 - 1.33) 2004 Modelled IHME
1.09 (0.88 - 1.33) 2003 Modelled IHME
1.09 (0.88 - 1.33) 2002 Modelled IHME
1.09 (0.88 - 1.33) 2001 Modelled IHME
1.09 (0.88 - 1.33) 2000 Modelled IHME
1.09 (0.88 - 1.32) 1999 Modelled IHME
1.08 (0.87 - 1.31) 1998 Modelled IHME
1.07 (0.86 - 1.30) 1997 Modelled IHME
1.06 (0.85 - 1.29) 1996 Modelled IHME
1.05 (0.85 - 1.29) 1995 Modelled IHME
1.05 (0.84 - 1.28) 1994 Modelled IHME
1.04 (0.84 - 1.28) 1993 Modelled IHME
1.04 (0.84 - 1.27) 1992 Modelled IHME
1.04 (0.84 - 1.27) 1991 Modelled IHME
1.03 (0.84 - 1.27) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
25.9 (22.10 - 29.70) 2014 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
35 (25 - 44) 2019 Modelled IHME
35 (26 - 44) 2018 Modelled IHME
35 (26 - 44) 2017 Modelled IHME
35 (25 - 44) 2016 Modelled IHME
34 (25 - 44) 2015 Modelled IHME
34 (25 - 44) 2014 Modelled IHME
34 (25 - 44) 2013 Modelled IHME
34 (25 - 43) 2012 Modelled IHME
34 (24 - 43) 2011 Modelled IHME
34 (24 - 43) 2010 Modelled IHME
34 (24 - 43) 2009 Modelled IHME
34 (24 - 43) 2008 Modelled IHME
34 (25 - 43) 2007 Modelled IHME
34 (25 - 43) 2006 Modelled IHME
34 (25 - 43) 2005 Modelled IHME
33 (24 - 43) 2004 Modelled IHME
33 (24 - 43) 2003 Modelled IHME
33 (24 - 42) 2002 Modelled IHME
33 (24 - 42) 2001 Modelled IHME
32 (24 - 42) 2000 Modelled IHME
33 (24 - 42) 1999 Modelled IHME
32 (23 - 42) 1998 Modelled IHME
32 (23 - 42) 1997 Modelled IHME
32 (23 - 42) 1996 Modelled IHME
32 (24 - 42) 1995 Modelled IHME
32 (24 - 42) 1994 Modelled IHME
32 (23 - 42) 1993 Modelled IHME
32 (23 - 42) 1992 Modelled IHME
32 (23 - 41) 1991 Modelled IHME
32 (23 - 42) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
4 (2.60 - 6) 2010 Survey/reported EMCDDA, 2016
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes
Year of birth dose introduction
2006
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.7 (%)
2019
(0.6 - 0.81(%))
IHME
HCV (RNA/cAg+)
1.11 (%)
2019
(0.9 - 1.37(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
406
2019
(289 - 553)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
575
2019
(407 - 774)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.06 (%)
2019, latest modelled
(0.04 - 0.08(%))
IHME

Prevalence PWID

HCV
25.90 (%)
2014, latest modelled
(22.10 - 29.70(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
99 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines